- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07942168
Doxorubicin Plus Dacarbazine Versus Doxorubicin Alone as First-Line Therapy for Metastatic or Recurrent Uterine Leiomyosarcoma (SARCOGYN)
Phase II Randomized Trial of Doxorubicin Plus Dacarbazine Versus Standard Doxorubicin as First-Line Therapy for Metastatic Uterine Leiomyosarcoma or t Uterine Leiomyosarcoma Recurrent After Surgical Treatment
The goal of this clinical trial is to learn whether adding dacarbazine to doxorubicin works better than doxorubicin alone as the first drug treatment for women with uterine leiomyosarcoma that is metastatic or has come back after surgery. A total of 100 participants will be randomly assigned to receive either doxorubicin alone or doxorubicin plus dacarbazine for up to 6 cycles of 21 days each. Researchers will compare how many participants are alive without disease progression 1 year after the start of treatment.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Leiomyosarcoma (LMS) represents 10-20% of soft-tissue sarcomas and has a poor prognosis in advanced stages. Retrospective multicenter data suggest that the doxorubicin plus dacarbazine combination improves progression-free survival (9.2 vs. 4.8 months) and response rates (30.9% vs. 25.6%) over doxorubicin alone in the advanced disease setting; however, this has never been investigated in randomized trials. This single-center, open-label trial compares doxorubicin plus dacarbazine with doxorubicin alone as first-line systemic therapy in patients with metastatic uterine leiomyosarcoma or with disease recurrence after prior surgical treatment.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Alexander Anokhin, PhD
- Telefonnummer: +7-915-518-85-00
- E-post: anokhinaleks@mail.ru
Studieorter
-
-
-
Moscow, Ryssland
- Rekrytering
- Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" оf the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO)
-
Kontakt:
- Alexander Anokhin, PhD
- Telefonnummer: +7-915-518-85-00
- E-post: anokhinaleks@mail.ru
-
Kontakt:
- Alexey Rumyantsev, PhD
- Telefonnummer: +7-499-324-10-87
- E-post: a.rumyantsev@ronc.ru
-
Huvudutredare:
- Alexander Anokhin, PhD
-
Underutredare:
- Alexey Rumyantsev, PhD
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
- Morphologically verified uterine leiomyosarcoma
- Age 18 to 70 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Metastatic disease at diagnosis, or disease recurrence after prior surgical treatment for localized disease
- No prior systemic anticancer therapy
- No contraindications to doxorubicin and dacarbazine
- Metastatic or recurrent disease confirmed by contrast-enhanced computed tomography (CT) of the chest, abdomen and pelvis (contrast-enhanced magnetic resonance imaging (MRI) of the pelvis is allowed)
- Measurable disease on CT or MRI prior to randomization
- Consent to treatment at N.N. Blokhin National Medical Research Center of Oncology
- Consent to the proposed chemotherapy regimen
- Adequate bone marrow function: absolute neutrophil count ≥1.5×10⁹/L, platelets ≥100×10⁹/L
- Adequate liver function: bilirubin ≤1.5 × upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 × ULN
- Adequate cardiac function: satisfactory left ventricular systolic function
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Doxorubicin
Participants receive 6 cycles of Doxorubicin. Each cycle is 21 days. |
Doxorubicin 75 mg/m² IV infusion, Day 1, Q3W for 6 cycles in first line
Andra namn:
Doxorubicin 15 mg/m²/day IV 24-h continuous infusion, Days 1-4, Q3W for 6 cycles in first line
Andra namn:
|
|
Experimentell: Doxorubicin+Dacarbazine
Participants receive 6 cycles of Doxorubicin+Dacarbazine. Each cycle is 21 days. |
Doxorubicin 75 mg/m² IV infusion, Day 1, Q3W for 6 cycles in first line
Andra namn:
Doxorubicin 15 mg/m²/day IV 24-h continuous infusion, Days 1-4, Q3W for 6 cycles in first line
Andra namn:
Dacarbazine 187.5 mg/m²/day IV 24-h continuous infusion, Days 1-4, Q3W for 6 cycles in first line
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
1-year progression-free survival (PFS)
Tidsram: Time from enrollment to disease progression or relapse or death due to any cause, or data cut-off date at 1 year, whichever occured first (up to ~12 months)
|
1-year PFS is defined as time from enrollment to disease progression or relapse or death due to any cause at 1 year (12-month PFS) |
Time from enrollment to disease progression or relapse or death due to any cause, or data cut-off date at 1 year, whichever occured first (up to ~12 months)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Overall Survival
Tidsram: Time from enrollment to death due to any cause, or data cut-off date, whichever occurred first (up to ~36 months)
|
OS is defined as time from enrollment to death due to any cause |
Time from enrollment to death due to any cause, or data cut-off date, whichever occurred first (up to ~36 months)
|
|
Objective Response Rate
Tidsram: After 3 cycles ( week 9) and after 6 cycles (week 18); each cycle is 21 days
|
Proportion of patients achieving complete or partial response per RECIST 1.1 |
After 3 cycles ( week 9) and after 6 cycles (week 18); each cycle is 21 days
|
|
incidence of Adverse events
Tidsram: During 6 cycles of treatment( each cucle is 21 days), up to 18 weeks
|
Proportion of patients experiencing adverse events in each treatment arm |
During 6 cycles of treatment( each cucle is 21 days), up to 18 weeks
|
Samarbetspartners och utredare
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer
- Neoplasmer efter histologisk typ
- Sarkom
- Neoplasmer, bindväv och mjukvävnad
- Neoplasmer, muskelvävnad
- Leiomyosarkom
- Organiska kemikalier
- Heterocykliska föreningar, 1-ring
- Heterocykliska föreningar
- Azoler
- Kolväten
- Kolväten, cykliska
- Kolhydrater
- Polycykliska aromatiska kolväten
- Kolväten, aromatisk
- Polycykliska föreningar
- Glykosider
- Triazenes
- Imidazoler
- Anthracykliner
- Naftakener
- Aminoglykosider
- Daunorubicin
- Doxorubicin
- Dakarbazin
Andra studie-ID-nummer
- 08202511001
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Individual participant data will not be shared because the informed consent form does not provide for sharing of data outside the research team.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .